Jessica Allegretti
Brigham and Women's Hospital
Appearances
- DateMay 8, 2023The gastrointestinal tract is a diverse and complex ecosystem shaped by continual interactions between host cells, nutrients, and the gut microbiota. Under homeostatic conditions, the human gut microbiota limits the growth of pathogenic bacteria and restricts the influence of resident pathobionts…
Moderators
Brigham and Women's HospitalMayo Clinic - DateMay 6, 2023Handout [https://ddw.digitellinc…
Presenters
Cedars-Sinai Medical CenterMayo Foundation for Medical Education and ResearchBrigham and Women's Hospital - DateMay 9, 2023BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Presenter
Speakers
- DateMay 8, 2023SOCIETY: AGA
Moderators
Brigham and Women's HospitalMayo Clinic - DateMay 8, 2023BACKGROUND: Recurrent _Clostridioides difficile _infection (rCDI) is a debilitating disease associated with significant healthcare burden and low quality of life. The greatest risk factor for rCDI is a history of recurrence, although older age (≥65 years) and comorbidities also increase risk…
Presenter
Brigham and Women's Hospital - DateMay 9, 2023BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…
Presenter
Brigham and Women's HospitalSpeakers
Western UniversityUniversity of PennsylvaniaUniversity of Chicago Division of the Biological Sciences - DateMay 19, 2024
Presenter
Brigham and Women's Hospital - DateMay 20, 2024The Phase 3 QUASAR Maintenance Study (NCT04033445) is a randomized-withdrawal, double-blind, placebo(PBO)-controlled, study that evaluated the efficacy and safety of maintenance treatment with subcutaneous (SC) guselkumab (GUS), an IL-23p19 subunit antagonist, in patients (pts) with moderately to s…
Presenter
University of Chicago Division of the Biological SciencesSpeakers
Brigham and Women's HospitalWestern UniversityUniversity of Pennsylvania - DateMay 18, 2024Background: We compared real-world outcomes of upadacitinib (upa) vs tofacitinib (tofa) for ulcerative colitis (UC) through 52 weeks…
Presenter
Speakers
University of North Carolina School of MedicineBrigham and Women's Hospital - DateMay 18, 2024SOCIETY: AGA This session will feature cutting-edge research on the multifaceted aspects of Clostridioides difficile colitis, presenting the latest findings in pathogenesis and innovative therapeutic approaches. Attendees will gain valuable insights into the molecular and immunological aspects of C…
Moderators
Brigham and Women's HospitalBrigham and Women's Hospital - DateMay 4, 2025This session is dedicted to our outstanding mentor awardee Lora Hooper We plan to invite three former trainees as additional speakers in this session…
Moderators
Cedars-Sinai Medical CenterBrigham and Women's Hospital - DateMay 5, 2025This is the second year of the debate format. We will cover two important clinical topics: Are high fiber diets really good for you? And should we be exploring off-label use of live biotherapeutic products? This will consist of speakers on each topic present different viewpoints on the question…
Moderators
McMaster UniversityBrigham and Women's Hospital - DateMay 6, 2025This session will feature a selection of the best abstracts submitted to the micobiome and microbial therapy section which encompass DGBI, IBD, cancer and liver disease…
Moderators
Cedars-Sinai Medical CenterBrigham and Women's Hospital - DateMay 3, 2025This session will explore the role of the microbiome in the pathogenesis of Clostridioides difficile colitis, assess real-world data on novel microbiome therapeutics, and review innovative delivery modalities for these treatments…
Moderators
Brigham and Women's HospitalBrigham and Women's Hospital